594492 Disclosed herein is a sodium salt of 5-cyclopropyl-2-2-{ [2-(2,6-difluorophenyl)pyrimidine)pyrimidin-5-yl]amino} benzoide acid (I) as a DHODH inhibitor； a pharmaceutical composition comprising said salt and one or more therapeutic agents selected selected from anti-TNF-alpha monoclonal antibodies, TNF-alpha Antagonists, calcineurin (PP-2B) Inhibitors / INS expression inhibitors, IL-1 receptor antagonists, anti-CD20 monoclonal antibodies, p38 Inhibitors, NF-kappaB (NFKB) activation inhibitors, dihydrofolate reductase (DHFR) inhibitors, JAK3 Inhibitors, MEK inhibitors, S1 P1 agonists, Interferons, inmunomodulators, and adenosine aminohydrolase inhibitors； and the use of said salt or pharmaceutical composition in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of dihydroorotate dehydrogenase, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondilytis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis and sarcoidosis.
